Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance

Nicholas J. WhiteMahidol University2020-01-272020-01-272019-10-11Malaria Journal. Vol.18, No.1 (2019)147528752-s2.0-85072941878https://repository.li.mahidol.ac.th/handle/20.500.14594/51004© 2019 The Author(s). Resistance threatens all our currently available anti-malarial drugs. Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs. TACTs are undergoing large-scale trials. If they prove safe, well-tolerated and efficacious then they should be deployed. This is in order to protect and extend the useful therapeutic life of the current generation of anti-malarial drugs, which are so essential for malaria control and elimination.Mahidol UniversityImmunology and MicrobiologyMedicineTriple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistanceReviewSCOPUS10.1186/s12936-019-2955-z